Literature DB >> 19602563

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Camelia Protopopescu1, François Raffi, Perrine Roux, Jacques Reynes, Pierre Dellamonica, Bruno Spire, Catherine Leport, Maria-Patrizia Carrieri.   

Abstract

OBJECTIVES: The aim of this study was to identify factors associated with non-adherence over a 10 year follow-up of the APROCO-COPILOTE cohort during the maintenance phase of highly active antiretroviral therapy (HAART).
METHODS: Overall, 1010 patients participated in this analysis, each having had at least 12 months of follow-up after HAART initiation and at least one self-reported adherence measure available during the follow-up period (month 12-month 120). Data collection was based on clinical records and self-administered questionnaires that gathered patients' psychosocial characteristics and experience with HIV disease and treatment. First, a generalized estimating equations (GEE) model was used to identify non-adherence predictors. Secondly, a Heckman two-stage approach was used in order to account for missing data bias and to measure the extent to which this could affect the results of the first model.
RESULTS: Non-adherent behaviour was reported by 747 patients (2070 visits). After correcting for the bias due to missing data, non-adherence was independently associated with side effects, having a three times or more daily dosing regimen, experience of being at clinical stage B/C and being diagnosed as HIV-positive for <6 months. Non-adherence was more likely among patients who were younger, had children, were born in the European Union, had depressive symptoms, consumed alcohol daily and declared a lack of support from their main partner. Adjusting for missing outcome data changed the pattern of predictors.
CONCLUSIONS: Reasons for non-adherence depended on both psychosocial conditions and treatment-related characteristics. To improve long-term patient outcomes for those at risk of adherence failure, tailor-made patient-specific psychosocial interventions and regimen-based strategies with improved tolerance need to be implemented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602563     DOI: 10.1093/jac/dkp232

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  36 in total

1.  The monoclonal CCR5 antibody PRO-140: the promise of once-weekly HIV therapy.

Authors:  Allan R Tenorio
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

2.  Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).

Authors:  T R Kiderlen; O Liesenfeld; D Schürmann; T Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

3.  Focus Group Evaluation of the LIVE Network-An Audio Music Program to Promote ART Adherence Self-Management.

Authors:  Marcia McDonnell Holstad; Maya Baumann; Ighovwerha Ofotokun; Steven J Logwood
Journal:  Music Med       Date:  2012-04-01

Review 4.  Substance use: impact on adherence and HIV medical treatment.

Authors:  Adam Gonzalez; Jennifer Barinas; Conall O'Cleirigh
Journal:  Curr HIV/AIDS Rep       Date:  2011-12       Impact factor: 5.071

5.  Quality of life of people with HIV/AIDS receiving antiretroviral therapy in Cuba: a cross-sectional study of the national population.

Authors:  Carlos Aragonés-López; Jorge Pérez-Ávila; Mary C Smith Fawzi; Arachu Castro
Journal:  Am J Public Health       Date:  2012-03-15       Impact factor: 9.308

6.  Challenges in initiating antiretroviral therapy in 2010.

Authors:  Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall
Journal:  Can J Infect Dis Med Microbiol       Date:  2010-08       Impact factor: 2.471

7.  The role of toxicity-related regimen changes in the development of antiretroviral resistance.

Authors:  Christa R Nevin; Jiatao Ye; Inmaculada Aban; Michael J Mugavero; David Jackson; Hui-Yi Lin; Jeroan Allison; James L Raper; Michael S Saag; James H Willig
Journal:  AIDS Res Hum Retroviruses       Date:  2011-03-21       Impact factor: 2.205

8.  Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Authors:  Giordano Madeddu; Stefano Rusconi; Alessandro Cozzi-Lepri; Simona Di Giambenedetto; Stefano Bonora; Alessia Carbone; Andrea De Luca; Nicola Gianotti; Antonio Di Biagio; Andrea Antinori
Journal:  Infection       Date:  2017-05-05       Impact factor: 3.553

9.  Self-reported medication adherence and symptom experience in adults with HIV.

Authors:  Caryl Gay; Carmen J Portillo; Ryan Kelly; Traci Coggins; Harvey Davis; Bradley E Aouizerat; Clive R Pullinger; Kathryn A Lee
Journal:  J Assoc Nurses AIDS Care       Date:  2011-03-05       Impact factor: 1.354

Review 10.  Challenges to eliminating the AIDS pandemic in China.

Authors:  Qi Tang; Hongzhou Lu
Journal:  Glob Health Med       Date:  2019-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.